Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes

Previous studies have shown that Imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor of c-KIT and platelet-derived growth factor receptors (PDGFR), is highly effective in c-KIT/CD117-positive gastrointestinal stromal tumors (GIST), especially in those having activating mutations in c-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer biology & therapy 2005-11, Vol.4 (11), p.1270-1274
Hauptverfasser:	Burger, Herman, den Bakker, Michael A, Kros, Johan M, van Tol, Hans, de Bruin, Alex M, Oosterhuis, Wolter, van den Ingh, Harry F G M, van der Harst, Erwin, de Schipper, Hans P, Wiemer, Erik A C, Nooter, Kees
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Benzamides DNA Mutational Analysis Enzyme Activation - genetics Gastrointestinal Stromal Tumors - genetics Gastrointestinal Stromal Tumors - pathology Humans Imatinib Mesylate Mutation Piperazines - pharmacology Proto-Oncogene Proteins c-kit - genetics Proto-Oncogene Proteins c-kit - metabolism Pyrimidines - pharmacology Receptor, Platelet-Derived Growth Factor alpha - genetics Receptor, Platelet-Derived Growth Factor alpha - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!